Alexander Drilon

38.6k total citations · 11 hit papers
382 papers, 13.1k citations indexed

About

Alexander Drilon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Alexander Drilon has authored 382 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 298 papers in Pulmonary and Respiratory Medicine, 221 papers in Oncology and 118 papers in Cancer Research. Recurrent topics in Alexander Drilon's work include Lung Cancer Treatments and Mutations (276 papers), Cancer Genomics and Diagnostics (107 papers) and Colorectal Cancer Treatments and Studies (79 papers). Alexander Drilon is often cited by papers focused on Lung Cancer Treatments and Mutations (276 papers), Cancer Genomics and Diagnostics (107 papers) and Colorectal Cancer Treatments and Studies (79 papers). Alexander Drilon collaborates with scholars based in United States, France and Germany. Alexander Drilon's co-authors include Marc Ladanyi, Emiliano Cocco, Maurizio Scaltriti, Maria E. Arcila, Mark G. Kris, Natasha Rekhtman, Charles M. Rudin, David M. Hyman, Ryma Benayed and Sai‐Hong Ignatius Ou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Alexander Drilon

363 papers receiving 12.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

NTRK fusion-positive cancers and TRK inhibitor therapy

2018 962 citations Emiliano Cocco, Maurizio Scaltriti et al. profile →
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

2019 409 citations Alexander Drilon et al. profile →
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

2019 366 citations James P. Solomon, Kerry Mullaney et al. profile →
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

2017 331 citations Jaclyn F. Hechtman, Ryma Benayed et al. The American Journal of Surgical Pathology profile →
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

2016 268 citations Alexander Drilon et al. Journal of Thoracic Oncology profile →
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Alexander Drilon et al. profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Herbert H. Loong et al. profile →

Peers

Countries citing papers authored by Alexander Drilon

Since Specialization

Citations

This map shows the geographic impact of Alexander Drilon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Drilon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Drilon more than expected).

Fields of papers citing papers by Alexander Drilon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Drilon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Drilon. The network helps show where Alexander Drilon may publish in the future.

Co-authorship network of co-authors of Alexander Drilon

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Drilon. A scholar is included among the top collaborators of Alexander Drilon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Drilon. Alexander Drilon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NTRK gene fusion testing and management in lung cancer 2024 ·Cancer Treatment Reviews ·Matteo Repetto, Marina Chiara Garassino, Herbert H. Loong, Fernando López‐Ríos, Tony Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R. Rudzinski, Alexander Drilon, Caicun Zhou	7
2	667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer 2023 ·Annals of Oncology ·David S. Hong, (unknown), Ray McDermott, Lin Shen, Miranda P. Dierselhuis, François Doz, Makoto Tahara, (unknown), (unknown), Nicoletta Brega, Theodore W. Laetsch, Alexander Drilon	3
3	Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function 2023 ·Journal of Thoracic Oncology ·Monica F. Chen, Guilherme Harada, Dazhi Liu, (unknown), Christina J. Falcon, Clare Wilhelm, Mark G. Kris, Alexander Drilon, Victoria Gutgarts	11
4	Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib 2023 ·Journal of Thoracic Oncology ·Yonina R. Murciano‐Goroff, Christina J. Falcon, Sabrina T. Lin, (unknown), (unknown), Dazhi Liu, Clare Wilhelm, Alexia Iasonos, Alexander Drilon	12
5	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim, (unknown), You Won Lee, (unknown), Chae Won Park, Seong Gu Heo, (unknown), Sung Sook Lee, Adam J. Schoenfeld, Alexander Drilon, Seok‐Gu Kang, Hyo Sup Shim, Min Hee Hong, J. Jean Cui, Hye Ryun Kim, Byoung Chul Cho	74
6	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden breakdown → 2019 ·Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi	289
7	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer 2019 ·Clinical Cancer Research ·James J. Harding, Andrew X. Zhu, Todd M. Bauer, Toni K. Choueiri, Alexander Drilon, Martin H. Voss, Charles S. Fuchs, Ghassan K. Abou‐Alfa, Sameera R. Wijayawardana, Xuejing Aimee Wang, Brian A. Moser, (unknown), Volker Wacheck, Johanna C. Bendell	32
8	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations 2019 ·Clinical Cancer Research ·Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman	115
9	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma 2018 ·The American Journal of Surgical Pathology ·Sarah Chiang, Paolo Cotzia, David M. Hyman, Alexander Drilon, William D. Tap, Lei Zhang, Jaclyn F. Hechtman, Denise Frosina, Achim A. Jungbluth, Rajmohan Murali, Kay J. Park, Robert A. Soslow, Esther Oliva, A. John Iafrate, Ryma Benayed, Marc Ladanyi, Cristina R. Antonescu	171
10	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers 2018 ·Clinical Cancer Research ·Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann	230
11	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Ken Suzawa, Michael Offin, Daniel Lu, (unknown), Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	83
12	RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition 2017 ·Clinical Cancer Research ·Takuo Hayashi, Patrice Desmeules, Roger S. Smith, Alexander Drilon, Romel Somwar, Marc Ladanyi	50
13	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets breakdown → 2016 ·Clinical Cancer Research ·Natasha Rekhtman, M. Catherine Pietanza, Matthew D. Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh Halpenny, Hangjun Wang, Shaozhou K. Tian, Anya M. Litvak, Paul K. Paik, Alexander Drilon, Nicholas D. Socci, John T. Poirier, Ronglai Shen, Michael F. Berger, André L. Moreira, William D. Travis, Charles M. Rudin, Marc Ladanyi	325
14	Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations 2016 ·Clinical Cancer Research ·(unknown), Romel Somwar, James D. Joseph, Roger S. Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, (unknown), Eric S. Martin, Gregory J. Riely, Jason Harris, Shunqi Yan, Wei Ge, Jennifer Oliver, Rupal Patel, Pratik S. Multani, Marc Ladanyi, Alexander Drilon	49
15	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities 2015 ·Clinical Cancer Research ·Anne Eaton, Alexia Iasonos, Mrinal M. Gounder, (unknown), Alexander Drilon, (unknown), G. Smith, S. Percy Ivy, David R. Spriggs, David M. Hyman	11
16	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping breakdown → 2015 ·Cancer Discovery ·Paul K. Paik, Alexander Drilon, Pang‐Dian Fan, Helena A. Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi	423
17	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches 2015 ·Clinical Cancer Research ·Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi	202
18	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer 2015 ·Clinical Cancer Research ·Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian Druker, Thomas O’Hare, Marc Ladanyi, Monika A. Davare	128
19	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking 2014 ·Clinical Cancer Research ·Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi	106
20	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions 2012 ·Clinical Cancer Research ·Yoshiyuki Suehara, Maria E. Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, (unknown), Alexander Drilon, Udayan Guha, Valerie W. Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer A. Rizvi, Raya Khanin, Marc Ladanyi	132

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact